Skip to main content
Equibles
ALZN logo

ALZN · Alzamend Neuro, Inc.

Track ALZN — free

Use ALZN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.66 -0.01 (-0.30%) At close · Aug 28
Rebalance outlook locked
Going-concern doubt — flagged Jul 22, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors create substantial doubt about our ability to continue as a going concern for at least one year after the date that our audited financial statements are issued.”
View the 10-K filed Jul 22, 2026
Market Cap
$7.95M
Shares
4.79M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.66 Open$1.64 Day$1.64–1.72 52W close$0.86–2.62 Avg vol 30d85K Short int177K · 3.7% float · 3.7d Short vol37% DataMay 2025–Aug 2026 Filing10-K · Jul 22

Raw chart and full-history price indicators begin at the captured split on May 12, 2025; bars on opposite sides are not compared.

Up next

FQ2-27 quarter ends
~Oct 30, 2026 Est
Latest filing: 10-K
filed Jul 22, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Buy Momentum Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 14.4 · calm Equity put/call 0.62
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +3%
above
Price vs 50-day avg +23%
above
RSI (14) 67
neutral
MACD trend Positive
52-week position 46%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return +27%
trailing
6-month return −21%
trailing
YTD return −9%
this year
Relative strength −34%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Distributing
-8% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.69% of float · ▼ -25.3% MoM · 3.7 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
12 holders — mid 3-yr range
Squeeze score 64
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 76%
annualized · 1-yr
Max drawdown −67%
past year
ATR 6.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+3% Bullish
Price vs 50-day avg
+23% Bullish
RSI (14)
67 Neutral
MACD trend
Positive Bullish
52-week position
46% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Distributing
-8% holders QoQ · +2 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
3.69% of float · ▼ -25.3% MoM · 3.7 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
12 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $2 · 46% Range high $3
vs 200-day avg +3% vs 50-day avg +23%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ALZN
Alzamend Neuro, Inc.
this stock
$7.95M -8.8% — — 3.7%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $137.30B +19.5% +46.2% 31.6 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.27B +2.9% +20.8% 19.6 2.3%
ARGX
Argenx SE
 $63.63B +21.7% — — 1.9%
CSLLY
Csl Ltd
 $59.23B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
12
% held
56.8%
Net QoQ
+2.0M sh
Top holder
KMT WEALTH MANAGEMENT, LLC
Held Float
View
Held by Funds
Fund positions
4
View
Short & Settlement
Short Interest Falling
Shares short
176.6K
Days to cover
3.7d
Change
-59.8K sh
View
Short Volume
Short vol %
37%
As of
Aug 28, 2026
Short Total
View
Fails to Deliver
FTD shares
1.7K
Value
$2.2K
As of
Jul 28, 2026
View
Off-Exchange
Off-exchange %
45.8%
Week of
Jul 20, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-8.8M
EPS diluted
$-2.63
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 3, 2026
This year
8
View
Proposed Sales
Value
$278.7K
Shares
516.1K
Filed
May 9, 2025
View
Earnings & Events
Earnings Calls Upcoming
Next call
Nov 18, 2026
View
Investor Relations
Upcoming events
2
View

Performance

Raw-price comparisons begin at the captured split on May 12, 2025; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
ALZN +6.4% +26.7% -21.0% +26.7% -8.8%
SPY +0.5% +3.0% +13.4% +3.0% +12.8%
vs SPY +5.9% +23.7% -34.4% +23.7% -21.6%
Key facts CIK 1677077 CUSIP 02262M605 13F (30d) 11 filings 10 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)